National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Summary

The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol.

Conditions

• Non-Small Cell Lung Cancer
• Carcinoma, Squamous Cell
• Adenocarcinoma

Interventions

DRUG

AZD4547

FGFR Inhibitor

DRUG

Vistusertib

MTORC1/2 Inhibitor

DRUG

Palbociclib

CDK4/6 Inhibitor

DRUG

Crizotinib

ALK/MET/ROS1 Inhibitor

DRUG

Selumetinib

MEK Inhibitor

DRUG

Docetaxel

Taxane, anti-mitotic cytotoxic chemotherapy

DRUG

AZD5363

AKT Inhibitor

DRUG

Osimertinib

EGFRm+ T790M+ Inhibitor

DRUG

Durvalumab

Anti-PDL1

DRUG

Sitravatinib

VEGFR Inhibitor

DRUG

AZD6738

ATR inhibitor

Sponsors & Collaborators

• Cancer Research UK

  collaborator OTHER

• AstraZeneca

  collaborator INDUSTRY

• Pfizer

  collaborator INDUSTRY

• Experimental Cancer Medicine Centres

  collaborator OTHER

• Mirati Therapeutics Inc.

  collaborator INDUSTRY

• University of Birmingham

  lead OTHER

Principal Investigators

• Gary W Middleton · University of Birmingham

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-05-13

Primary Completion

2023-11-29

Completion

2023-11-29

Countries

• United Kingdom

Study Locations